Tamoxifen (Tam) and fulvestrant (Fulv) are major representatives of selective ER modulators (SERMs) and selective ER degraders/downregulators (SERDs), respectively, belonging thus to routine therapy of patients with ER+ breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.